<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Respiratory syncytial virus infection: Prevention in infants and children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Respiratory syncytial virus infection: Prevention in infants and children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Respiratory syncytial virus infection: Prevention in infants and children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frederick E Barr, MD, MBA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barney S Graham, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H104280778"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Respiratory syncytial virus (RSV) causes acute respiratory tract illness in persons of all ages. The clinical manifestations vary with age, health status, and whether the infection is primary or secondary.</p><p>The prevention of RSV infection in infants and children will be discussed here. The epidemiology, microbiology, clinical manifestations, diagnosis, and treatment of RSV infection and bronchiolitis are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6001.html" rel="external">"Respiratory syncytial virus infection: Treatment in infants and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6018.html" rel="external">"Bronchiolitis in infants and children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">"Bronchiolitis in infants and children: Treatment, outcome, and prevention"</a>.)</p><p></p><p class="headingAnchor" id="H104278842"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>Transmission of RSV predominantly occurs through inoculation of nasopharyngeal or ocular mucous membranes after direct contact with virus-containing secretions or fomites. General measures to prevent RSV infection are focused on decreasing inoculation. They include [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hand washing in all settings, particularly when high-risk infants are at risk for exposure to respiratory infections from older siblings [<a href="#rid3">3,4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Practicing cough hygiene (eg, covering the mouth and nose with a tissue, upper sleeve, or elbow when coughing or sneezing; immediately disposing of the tissue in a waste receptacle; washing hands)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of exposure to tobacco and other smoke (see  <a class="medical medical_review" href="/z/d/html/6376.html" rel="external">"Control of secondhand smoke exposure", section on 'Strategies to prevent secondhand smoke exposure'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restricting participation in childcare during RSV season for high-risk infants (if possible)</p><p></p><p class="headingAnchor" id="H104278849"><span class="h1">INFECTION CONTROL IN THE HEALTH CARE SETTING</span><span class="headingEndMark"> — </span>RSV is highly contagious and can cause serious health care-associated infections, particularly in high-risk patients (eg, those with premature birth, congenital heart or lung disease, hematopoietic cell or solid organ transplant, older adults with multiple underlying conditions). Rapid diagnosis of RSV infection is essential for implementation of measures to prevent health care-associated infection in high-risk patients. (See  <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Diagnosis'</a>.)</p><p>The types of infection control precautions are determined by the setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Inpatient and ambulatory settings – In both inpatient and ambulatory settings, the Centers for Disease Control and Prevention recommends standard and contact precautions for prevention of RSV [<a href="#rid5">5,6</a>]. Hand washing and appropriate use of gloves are probably the most important infection control measures, but surgical mask, eye protection, and disposable gowns for health care providers should be used when there is a chance of exposure to infectious respiratory secretions [<a href="#rid5">5-10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inpatient settings – In the inpatient setting, it is particularly important to avoid exposing immunocompromised children (eg, those with allogeneic hematopoietic cell transplantation) to RSV. In addition to standard and contact precautions, isolation of patients in private rooms or in rooms with other RSV-infected patients (cohorting patients) and limited transport of patients from their rooms also are recommended [<a href="#rid5">5,11-13</a>]. During outbreaks, personnel caring for RSV-infected patients should be restricted from caring for uninfected patients as often as possible (cohorting personnel).</p><p></p><p class="bulletIndent1">Health care personnel and visitors with upper respiratory tract infections should be restricted from contact with high-risk patients as much as is practical, especially during the peak RSV transmission months [<a href="#rid11">11,13,14</a>]. Health care personnel should have continuing education about the symptoms, epidemiology, diagnosis, and transmission of RSV. (See  <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children"</a>.)</p><p></p><p class="headingAnchor" id="H3257543338"><span class="h1">IMMUNOPROPHYLAXIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a> –<strong> </strong>Nirsevimab is a monoclonal antibody that targets the prefusion conformation of the RSV F glycoprotein. It has a long half-life and potent neutralizing activity. A dose of nirsevimab is expected to provide protection for at least five months such that only one dose is needed at the beginning of the RSV season. Nirsevimab was approved by the US Food and Drug Administration in 2023 for all infants and should be used in place of <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a>, even for premature infants and those with other risk factors, unless nirsevimab is not available [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and effectiveness</strong> – In multicenter, placebo-controlled trials in otherwise healthy infants born at ≥29 weeks' gestation entering their first RSV season, a single injection of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> appeared to be safe and effective in preventing RSV lower respiratory tract infection (LRTI) that required medical attention (eg, emergency department or clinic visit) and RSV-associated hospitalization [<a href="#rid17">17-19</a>]. In one study, more than 1400 infants born between 29 and 35 weeks' gestation were randomly assigned in a 2:1 ratio to receive a dose of nirsevimab or placebo [<a href="#rid17">17</a>], and in another study, more than 1400 infants who were born ≥35 weeks' gestation were randomly assigned in the same manner [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">In the first study, infants assigned to receive <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> had fewer RSV LRTIs requiring medical attention than those receiving placebo (2.6 versus 9.5 percent, relative efficacy 70.1 percent, 95% CI 52.3- to 81.2), and the incidence of hospitalization at five months was lower (0.8 versus 4.1 percent, relative efficacy 78.4 percent, 95% CI 51.9 to 90.3) [<a href="#rid17">17</a>]. Similarly, in the second study, fewer infants receiving nirsevimab required medical attention (1.2 versus 5.0 percent, relative efficacy 74.5 percent, 95% CI 49.6 to 87.1), and they had a lower incidence of hospitalization (0.6 versus 1.6 percent, relative efficacy 62.1 percent, 95% CI -8.6 to 86.8) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">In another study conducted in France, Germany, and the United Kingdom, more than 8000 otherwise healthy infants ≤12 months, born at ≥29 weeks' gestation, and entering their first RSV season were assigned to receive one dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> or no intervention [<a href="#rid20">20</a>]. The group who received nirsevimab had fewer hospitalizations for RSV-associated LRTI (0.3 versus 1.5 percent, efficacy 83.2 percent, 95% CI 67.8-92.0) and fewer infants with an oxygen saturation &lt;90 percent (0.1 versus 0.5 percent, efficacy 75.7 percent, 95% CI 32.8-92.9).</p><p></p><p>We agree with the recommendations of the Centers for Disease Control and Prevention's (CDC) and the American Academy of Pediatrics' (AAP) for administering <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a>, and these are reflected in the following sections  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef143565" href="/z/d/graphic/143565.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef142933" href="/z/d/graphic/142933.html" rel="external">table 1</a>) [<a href="#rid15">15,21,22</a>].</p><p class="headingAnchor" id="H1089585792"><span class="h2">First RSV season</span></p><p class="headingAnchor" id="H1172460962"><span class="h3">Infants &lt;8 months</span></p><p class="headingAnchor" id="H4031503749"><span class="h4">Birthing parent did not receive RSV vaccination during pregnancy</span><span class="headingEndMark"> — </span>We recommend that <strong>all</strong> infants younger than eight months who are born during the RSV season or are entering their first RSV season receive one dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> if the birthing parent did not receive RSV vaccination during pregnancy or the vaccination status of the birthing parent is unknown  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a>). Details regarding the dose and administration of nirsevimab are presented below. (See <a class="local">'Administration'</a> below.)</p><p>If <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> is not received on time, it should be administered at any time during the RSV season unless the infant has reached eight months of age.</p><p class="headingAnchor" id="H4194636511"><span class="h4">Birthing parent did receive RSV vaccine during pregnancy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination occurred &lt;14 days before delivery</strong> – We recommend that <strong>all</strong> infants who are born during the RSV season or are entering their first RSV season receive one dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> if their birthing parent was vaccinated within 14 days of delivery  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination occurred ≥14 days before delivery</strong> – We do not recommend immunoprophylaxis for infants whose birthing parent was vaccinated more than 14 days before delivery  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">However, if any of the following exceptions apply, <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> may be given if the provider judges that the incremental benefit to the infant is warranted: the birthing parent has a condition that may prevent an adequate immune response or is associated with reduced transplacental antibody transfer (eg, persons with immunocompromising conditions); the infant requires cardiopulmonary bypass or extracorporeal membrane oxygenation; or the infant is at substantial increased risk for severe RSV disease (eg, hemodynamically significant heart disease, intensive care admission, oxygen requirement at discharge).</p><p></p><p class="bulletIndent1">Details regarding the timing and dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> are presented below. (See <a class="local">'Administration'</a> below.)</p><p></p><p class="headingAnchor" id="H254485155"><span class="h3">Infants ≥8 months</span></p><p class="bulletIndent1"><span class="glyph">●</span>Healthy infants ≥8 months old who did not receive a dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> on time are not eligible for a catch-up dose  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants at increased risk for severe disease that did not receive <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> before eight months of age should receive one dose of nirsevimab. Criteria for increased risk are listed in the table  (<a class="graphic graphic_table graphicRef142933" href="/z/d/graphic/142933.html" rel="external">table 1</a>). Details regarding the timing and dose of nirsevimab are presented below  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a>). (See <a class="local">'Administration'</a> below.)</p><p></p><p class="headingAnchor" id="H1403491549"><span class="h2">Second RSV season</span></p><p class="headingAnchor" id="H2907252079"><span class="h3">All infants &lt;8 months</span><span class="headingEndMark"> — </span>All infants who did not receive <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> during their first RSV season and are younger than eight months entering their second RSV season should receive a dose of nirsevimab. On the other hand, healthy infants who received nirsevimab during their first RSV season should not receive another dose, even if they are less than eight months of age  (<a class="graphic graphic_algorithm graphicRef143565" href="/z/d/graphic/143565.html" rel="external">algorithm 2</a>).</p><p>Details regarding the timing and dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> are presented below. (See <a class="local">'Administration'</a> below.)</p><p class="headingAnchor" id="H2686625044"><span class="h3">Infants 8 through 19 months at increased risk for severe disease</span><span class="headingEndMark"> — </span>We suggest that infants and children who are 8 through 19 months old and at increased risk for severe RSV receive a second dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> upon entry into their second RSV season  (<a class="graphic graphic_algorithm graphicRef143565" href="/z/d/graphic/143565.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef142933" href="/z/d/graphic/142933.html" rel="external">table 1</a>). This advice also applies to infants who received <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> during their first RSV season.</p><p>Criteria for increased risk of severe disease include [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with bronchopulmonary dysplasia (BPD; also known as chronic lung disease of prematurity) who required medical support (eg, chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the six-month period before the start of the RSV season</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children who are severely immunocompromised</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with cystic fibrosis who have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or have weight-for-length &lt;10<sup>th</sup> percentile</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>American Indian and Alaska Native children</p><p></p><p>For the purpose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> prophylaxis, we use the definition for BPD provided in the AAP guidelines: gestational age &lt;32 weeks and a requirement for supplemental oxygen for the first 28 days after birth [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Definitions and severity of BPD'</a>.)</p><p>Details regarding the timing and dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> are presented below. (See <a class="local">'Administration'</a> below.)</p><p class="headingAnchor" id="H1139152020"><span class="h2">Administration</span></p><p class="headingAnchor" id="H1289703431"><span class="h3">Timing</span><span class="headingEndMark"> — </span>RSV season in most of the continental United States generally runs from October to the end of March. Because this varies geographically, health care providers should adjust the timing of immunoprophylaxis if indicated by their community's RSV activity.</p><p class="bulletIndent1"><span class="glyph">●</span>Infants born during RSV season – <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a> should be administered within the first week of life. If the infant's hospitalization after birth is extended due to prematurity or other problems, the nirsevimab should be administered shortly before or promptly after hospital discharge.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants born before RSV season – <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a> should be administered shortly before the season begins. Eligible infants who do not receive nirsevimab before the RSV season begins may receive it at any time before the season ends. For healthy infants, eligibility requires that they be &lt;8 months old at the time of administration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with increased risk for severe disease entering their second RSV season – All children ≤19 months with increased risk should receive a second dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> just before the start of the RSV season. (See <a class="local">'Infants 8 through 19 months at increased risk for severe disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2815208246"><span class="h3">Dose</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> is based on weight and age.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infant's first RSV season</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight &lt;5 kg – One 50 mg intramuscular (IM) dose</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight ≥5 kg – One 100 mg IM dose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Child's second RSV season</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One 200 mg IM dose</p><p></p><p>When age-appropriate vaccines are indicated, simultaneous administration of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> with the vaccines is recommended.</p><p class="headingAnchor" id="H355864674"><span class="h2">Adverse events</span><span class="headingEndMark"> — </span>Adverse events reported in the two multicenter trials of healthy infants ≥29 weeks gestation were similar between the <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> groups and the placebo groups, including serious adverse events [<a href="#rid17">17,18</a>]. Additionally, there were no anaphylactic reactions. Five deaths (0.3 percent) occurred in the nirsevimab groups and three (0.3 percent) occurred in the placebo groups. None of the deaths were judged by the investigators to be related to nirsevimab or placebo.</p><p class="headingAnchor" id="H372111353"><span class="h2">Nirsevimab not available</span><span class="headingEndMark"> — </span>Prior to the development of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a>, <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> was the only monoclonal antibody available for the prevention of serious RSV LRTI in children at high risk. Palivizumab targets both the prefusion and postfusion conformation of the RSV F glycoprotein and has lower neutralizing activity than nirsevimab. When nirsevimab is not available, we suggest that palivizumab be used for infants that were previously designated by the AAP as high risk for severe RSV disease.</p><p><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">Palivizumab</a> is administered as five monthly IM injections during the RSV season. If <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> becomes available and &lt;5 doses of palivizumab have been administered, the infant should receive one dose of nirsevimab and no additional doses of palivizumab. Infants who have received nirsevimab should not receive palivizumab during the same RSV season.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">Palivizumab</a><strong> eligibility</strong> – Our suggested criteria for palivizumab prophylaxis are generally consistent with those of the AAP, which were reaffirmed in 2019  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>) [<a href="#rid23">23,24</a>]. However, recommendations for and availability of palivizumab prophylaxis vary geographically. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prematurity with BPD</strong> – The terminology for and definition of BPD (also known as neonatal chronic lung disease and chronic lung disease of prematurity) have changed over time. For the purpose of <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis, we use the definition for BPD provided in the AAP guidelines: gestational age &lt;32 weeks, 0 days and a requirement for supplementation oxygen for the first 28 days after birth [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4987.html" rel="external">"Bronchopulmonary dysplasia (BPD): Clinical features and diagnosis", section on 'Definitions and severity of BPD'</a>.)</p><p></p><p class="bulletIndent2">We suggest <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis for infants with BPD who have either of the following  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>) [<a href="#rid23">23,25</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age &lt;1 year at the start of RSV season.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Age 12 through 23 months and required medical therapy (eg, supplemental oxygen, glucocorticoids, diuretics) for BPD within six months of the start of RSV season.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prematurity without BPD</strong> – Suggestions for <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis among premature infants without BPD depend upon the degree of prematurity  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>) [<a href="#rid23">23</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We suggest that <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> be administered to preterm infants without BPD who were born at &lt;29 weeks' gestation and are younger than 12 months of age at the start of RSV season.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For preterm infants without BPD who were born between 29 and 32 weeks' gestation and who are younger than 12 months of age at the start of RSV season, the authors of this topic make decisions on a case-by-case basis after discussing the potential benefits and costs with the infant's caregiver(s). Recommendations from professional societies regarding <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis in preterm infants without BPD in this gestational age range are inconsistent [<a href="#rid23">23,26</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent3">Additional factors to be considered in the decision include risk factors for severe disease (eg, age &lt;4 months during peak RSV season, childcare attendance, older siblings in the home, parental smoking, prevalence of RSV in the community) and out-of-pocket costs [<a href="#rid3">3,26-28</a>]. (See  <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital heart disease</strong> – Decisions regarding <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis for children with congenital heart disease (CHD) should be individualized according to the degree of cardiovascular compromise  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>) and made in consultation with the infant's cardiologist.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">Palivizumab</a> prophylaxis is more likely to be beneficial for infants &lt;12 months of age with either of the following [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Acyanotic heart disease receiving medication to control heart failure and will require cardiac surgical procedures.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Moderate to severe pulmonary hypertension.</p><p></p><p class="bulletIndent2">Infants with CHD who are receiving <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis and require cardiac bypass during the RSV season should receive a postoperative dose of palivizumab 15 mg/kg IM as soon as they are medically stable because the mean serum palivizumab concentration has been observed to decrease by more than 50 percent after cardiac bypass [<a href="#rid23">23,29,30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other potential target groups</strong> – We consider <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis on a case-by-case basis for children in other target groups who are at increased risk for RSV-associated morbidity or who have limited access to care for severe respiratory illness  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>). Children in the first two target groups below may be at risk for prolonged hospitalization related to LRTIs. However, population-based and prospective studies defining the risk of RSV hospitalization in these children are lacking [<a href="#rid1">1,23</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Neuromuscular disorder</strong> – Children with neuromuscular disease that impairs the ability to clear secretions from the upper airway (eg, ineffective cough) should be considered for <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis during their first year of life.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pulmonary abnormalities</strong> – Children with pulmonary malformations, tracheoesophageal fistula, upper airway conditions, or conditions requiring tracheostomy should be considered for <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis during their first year of life.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Immunocompromised host</strong> – Although <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis has not been evaluated in immunocompromised children in controlled trials, children with severe immunodeficiencies (eg, severe combined immunodeficiency or severe acquired immunodeficiency, children younger than two years of age who have undergone lung transplantation, heart transplantation, or hematopoietic cell transplantation) may benefit from palivizumab prophylaxis [<a href="#rid1">1,23</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Down syndrome</strong> – Prophylactic <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> may be warranted for infants younger than 12 months of age with Down syndrome and additional risk factors for RSV LRTI, including birth during the peak of RSV season.</p><p></p><p class="bulletIndent3">Down syndrome, independent of prematurity or hemodynamically significant CHD, appears to be a risk factor for RSV LRTI and hospitalization [<a href="#rid31">31-34</a>]. In addition, children with Down syndrome who are admitted to the hospital with RSV infection appear to be at increased risk for severe RSV disease (eg, need for intensive care, longer hospital stay) [<a href="#rid35">35-38</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Native American and Alaska Native infants</strong> – A lower threshold for administration of <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> prophylaxis may be warranted for Native American and Alaska Native infants &lt;12 months of age because of the higher rates of RSV hospitalization and the challenges associated with transport of such infants from remote locations [<a href="#rid1">1,23,39-43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">Palivizumab</a><strong> dose and schedule</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regimen – The dose of <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> is 15 mg/kg IM once per month typically for a maximum of five doses, with a maximum interval of 35 days between doses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Timing of first dose – The first dose is administered before the RSV season begins [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent2">Infants who qualify for <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> but remain hospitalized when the first dose is due may receive the first dose 48 to 72 hours before discharge home or promptly after discharge (insurance coverage may be a factor in this decision for infants in the United States) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Number of doses – When an infant qualifies for initiation of prophylaxis at the beginning of the RSV season and is not hospitalized for breakthrough RSV infection, all five doses should be administered, even if the infant becomes old enough that prophylaxis is no longer indicated [<a href="#rid23">23</a>]. As an example, an infant born at &lt;29 weeks' gestation who is without BPD and turns 12 months old in January should still receive immunoprophylaxis in February and March.</p><p></p><p class="bulletIndent2">Fewer than five doses may be administered to an infant who qualifies for <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> and is born toward the end of the RSV season [<a href="#rid23">23</a>]. For example, an infant born in February typically would receive only two doses (February and March) but may receive more if the local RSV season extends into April or May. The hospital laboratory or health department may have data to help determine when the local RSV season has ended.</p><p></p><p class="bulletIndent2">Although abbreviated schedules of three or four doses have been used, studies evaluating the effectiveness of abbreviated or partial schedules in preventing RSV hospitalization have conflicting results [<a href="#rid44">44-46</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">Palivizumab</a> does not interfere with routine childhood immunizations, including live viral vaccines (eg, measle, mumps, rubella vaccine; <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Home administration</strong> – Administration of <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> in the home setting may increase adherence to the schedule [<a href="#rid47">47-51</a>]. In a registry study, administration in the home setting was associated with a decreased rate of RSV-associated hospitalization (0.4 versus 1.2 percent when administered in an outpatient setting) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breakthrough RSV infection</strong> – Immunoprophylaxis should be discontinued if the infant experiences breakthrough infection requiring hospitalization. The risk of a second RSV hospitalization during the same season is low (&lt;0.5 percent) [<a href="#rid52">52</a>]. In addition, repeat infections generally are less severe than the initial infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – Rare cases of severe hypersensitivity reactions have been described after an initial dose, as well as after reexposure [<a href="#rid53">53,54</a>].</p><p></p><p class="headingAnchor" id="H2931696294"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112263.html" rel="external">"Society guideline links: Bronchiolitis in infants and children"</a>.)</p><p class="headingAnchor" id="H104278912"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1213.html" rel="external">"Patient education: Bronchiolitis and RSV in infants and children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H104280568"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – General measures to prevent RSV infection include hand washing, practicing cough hygiene, avoidance of tobacco and other smoke, and restricting participation in childcare during RSV season for high-risk infants (if possible). (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control in the health care setting</strong> – Measures for the prevention of health care-associated RSV infections include handwashing and appropriate use of gloves, masks, gowns, and eye protection for health care workers, isolation of patients in private rooms or in rooms with other RSV-infected patients (cohorting patients), and cohorting health care personnel. (See <a class="local">'Infection control in the health care setting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunoprophylaxis</strong> – <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a> is a monoclonal antibody that targets the prefusion conformation of the RSV F glycoprotein. It has a long half-life and potent neutralizing activity. A dose of nirsevimab is expected to provide protection for at least five months such that only one dose is needed at the beginning of the RSV season. Nirsevimab should be used in place of <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> unless nirsevimab is not available  (<a class="graphic graphic_algorithm graphicRef143564" href="/z/d/graphic/143564.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef143565" href="/z/d/graphic/143565.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef142933" href="/z/d/graphic/142933.html" rel="external">table 1</a>). (See <a class="local">'Immunoprophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <strong>all</strong> infants younger than eight months who are born during the RSV season or are entering their first RSV season, we recommend one dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> prophylaxis rather than no prophylaxis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>), unless the birthing parent received RSV vaccination at least 14 days prior to birth. (See <a class="local">'Infants &lt;8 months'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Healthy infants less than eight months old should only receive a dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> upon entering their second RSV season if they did not receive nirsevimab during their first RSV season. (See <a class="local">'All infants &lt;8 months'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants and children who are 8 through 19 months of age with increased risk for severe RSV, we suggest a second dose of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> upon entry into their second RSV season (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Infants 8 through 19 months at increased risk for severe disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limited supplies of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> may require prioritization of available supply.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> is not available, <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> should be provided to patients for whom it has been previously recommended  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>). (See <a class="local">'Nirsevimab not available'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a><strong> dose and schedule</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infant's first RSV season</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight &lt;5 kg – One 50 mg intramuscular (IM) dose</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight ≥5 kg – One 100 mg IM dose</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Child's second RSV season</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One 200 mg IM dose</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a> is administered shortly before the RSV season begins (infants younger than 8 months and those 8 through 19 months at increased risk for severe RSV disease) or within one week of birth for a newborn infant delivered shortly before or during the RSV season.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">Nirsevimab</a><strong> not available (</strong><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a><strong> prophylaxis)</strong> – Palivizumab, another monoclonal antibody that targets both the prefusion and postfusion conformation of the RSV F glycoprotein, was the only available immunoprophylaxis for severe RSV disease prior to the development of nirsevimab. Unlike nirsevimab, palivizumab requires monthly IM injections throughout the RSV season.</p><p></p><p class="bulletIndent1">The eligibility criteria for <a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">palivizumab</a> differ from those of <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">nirsevimab</a> and are outlined in the table  (<a class="graphic graphic_table graphicRef141499" href="/z/d/graphic/141499.html" rel="external">table 2</a>). (See <a class="local">'Nirsevimab not available'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9849" href="/z/d/drug information/9849.html" rel="external">Palivizumab</a><strong> dose and schedule</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>15 mg/kg IM once per month (maximum of five doses)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>First dose administered shortly after birth or just before RSV season begins</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Interval between doses should not exceed 35 days</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Prophylaxis should be discontinued if infant hospitalized for breakthrough RSV infection</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:e620.</a></li><li><a class="nounderline abstract_t">Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014; 134:e1474.</a></li><li><a class="nounderline abstract_t">Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis 2014; 209:1685.</a></li><li><a class="nounderline abstract_t">Hall CB, Geiman JM, Biggar R, et al. Respiratory syncytial virus infections within families. N Engl J Med 1976; 294:414.</a></li><li class="breakAll">Centers for Disease Control and Prevention, Guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings (2007), updated July 2019. Available at: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html (Accessed on March 18, 2020).</li><li class="breakAll">Centers for Disease Control and Prevention. Guide to infection prevention for outpatient settings: Minimum expectations for safe care. Available at: https://www.cdc.gov/hai/settings/outpatient/outpatient-care-guidelines.html (Accessed on July 09, 2020).</li><li><a class="nounderline abstract_t">Agah R, Cherry JD, Garakian AJ, Chapin M. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Routine isolation procedure vs routine procedure supplemented by use of masks and goggles. Am J Dis Child 1987; 141:695.</a></li><li><a class="nounderline abstract_t">Gala CL, Hall CB, Schnabel KC, et al. The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection. JAMA 1986; 256:2706.</a></li><li><a class="nounderline abstract_t">Leclair JM, Freeman J, Sullivan BF, et al. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med 1987; 317:329.</a></li><li><a class="nounderline abstract_t">Thorburn K, Kerr S, Taylor N, van Saene HK. RSV outbreak in a paediatric intensive care unit. J Hosp Infect 2004; 57:194.</a></li><li><a class="nounderline abstract_t">Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) 1989; 68:269.</a></li><li><a class="nounderline abstract_t">Krasinski K, LaCouture R, Holzman RS, et al. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission. J Pediatr 1990; 116:894.</a></li><li><a class="nounderline abstract_t">Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53:1.</a></li><li class="breakAll">Welliver RC, Hall CB. Respiratory syncytial virus. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison G, Kaplan SL, et al (Eds), Elsevier, Philadelphia 2018. p.1780.</li><li><a class="nounderline abstract_t">Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:920.</a></li><li class="breakAll">FDA Approves New Drug to Prevent RSV in Babies and Toddlers. Press Release, US Food and Drug Administration, 2023. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers.</li><li><a class="nounderline abstract_t">Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med 2020; 383:415.</a></li><li><a class="nounderline abstract_t">Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med 2022; 386:837.</a></li><li><a class="nounderline abstract_t">Muller WJ, Madhi SA, Seoane Nuñez B, et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med 2023; 388:1533.</a></li><li><a class="nounderline abstract_t">Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med 2023; 389:2425.</a></li><li class="breakAll">Monoclonal Antibody Products for Infants and Young Children. Centers for Disease Control and Prevention, 2023. https://www.cdc.gov/rsv/clinical/index.html#antibody-product-for-children (Accessed on August 15, 2023).</li><li class="breakAll">ACIP and AAP Recommendations for Nirsevimab publications.aap.org/redbook/resources/25379/ (Accessed on August 18, 2023).</li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415.</a></li><li><a class="nounderline abstract_t">AAP Publications Reaffirmed. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Winterstein AG, Choi Y, Meissner HC. Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease. JAMA Pediatr 2018; 172:154.</a></li><li class="breakAll">Goldstein M, Phillips R, DeVincenzo JP, et al. Respiratory syncytial virus (RSV) prevention clinical practice guideline: an evidence-based interdisciplinary collaboration. Available at: http://www.neonatologytoday.net/newsletters/nt-oct17.pdf (Accessed on July 15, 2020).</li><li><a class="nounderline abstract_t">Houben ML, Bont L, Wilbrink B, et al. Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics 2011; 127:35.</a></li><li><a class="nounderline abstract_t">Haerskjold A, Kristensen K, Kamper-Jørgensen M, et al. Risk Factors for Hospitalization for Respiratory Syncytial Virus Infection: A Population-based Cohort Study of Danish Children. Pediatr Infect Dis J 2016; 35:61.</a></li><li><a class="nounderline abstract_t">Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532.</a></li><li><a class="nounderline abstract_t">Tulloh R, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13:420.</a></li><li><a class="nounderline abstract_t">Beckhaus AA, Castro-Rodriguez JA. Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Mitra S, El Azrak M, McCord H, Paes BA. Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis. J Pediatr 2018; 203:92.</a></li><li><a class="nounderline abstract_t">Huggard D, Molloy EJ. Question 1: Palivizumab for all children with Down syndrome? Arch Dis Child 2019; 104:94.</a></li><li><a class="nounderline abstract_t">Löwensteyn YN, Phijffer EWEM, Simons JVL, et al. Respiratory Syncytial Virus-related Death in Children With Down Syndrome: The RSV GOLD Study. Pediatr Infect Dis J 2020; 39:665.</a></li><li><a class="nounderline abstract_t">Mori M, Morio T, Ito S, et al. Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome. J Infect Chemother 2014; 20:455.</a></li><li><a class="nounderline abstract_t">Stagliano DR, Nylund CM, Eide MB, Eberly MD. Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr 2015; 166:703.</a></li><li><a class="nounderline abstract_t">Galleguillos C, Galleguillos B, Larios G, et al. Down's syndrome is a risk factor for severe lower respiratory tract infection due to respiratory syncytial virus. Acta Paediatr 2016; 105:e531.</a></li><li><a class="nounderline abstract_t">Lee YI, Peng CC, Chiu NC, et al. Risk factors associated with death in patients with severe respiratory syncytial virus infection. J Microbiol Immunol Infect 2016; 49:737.</a></li><li><a class="nounderline abstract_t">Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002; 110:e20.</a></li><li><a class="nounderline abstract_t">Lowther SA, Shay DK, Holman RC, et al. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J 2000; 19:11.</a></li><li><a class="nounderline abstract_t">Bruden DJ, Singleton R, Hawk CS, et al. Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children. Pediatr Infect Dis J 2015; 34:945.</a></li><li><a class="nounderline abstract_t">O'Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 2015; 15:1398.</a></li><li><a class="nounderline abstract_t">Banerji A, Ng K, Moraes TJ, et al. Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic. CMAJ Open 2016; 4:E623.</a></li><li><a class="nounderline abstract_t">Krilov LR, Masaquel AS, Weiner LB, et al. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis. BMC Pediatr 2014; 14:261.</a></li><li><a class="nounderline abstract_t">Lavoie PM, Solimano A, Taylor R, et al. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab. JAMA Pediatr 2016; 170:174.</a></li><li><a class="nounderline abstract_t">Claydon J, Popescu CR, Shaiba L, et al. Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis. CMAJ Open 2019; 7:E88.</a></li><li><a class="nounderline abstract_t">Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28:511.</a></li><li><a class="nounderline abstract_t">Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004; 23:318.</a></li><li><a class="nounderline abstract_t">Hand IL, Noble L, Geiss D, Shotkin A. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J 2008; 27:175.</a></li><li><a class="nounderline abstract_t">Frogel M, Nerwen C, Boron M, et al. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Infect Dis J 2008; 27:870.</a></li><li><a class="nounderline abstract_t">Whelan B, Musters E, Murray A, et al. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs Ther Perspect 2016; 32:119.</a></li><li><a class="nounderline abstract_t">Yamaguchi M, Sano Y, Dapat IC, et al. High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan. J Clin Microbiol 2011; 49:1034.</a></li><li class="breakAll">Synagis (palivizumab) injection. US Food &amp; Drug Administration (FDA) approved product information. Revised May, 2017.  US National Library of Medicine. Available online at https://www.dailymed.nlm.nih.gov/dailymed/ (Accessed on July 14, 2020).</li><li><a class="nounderline abstract_t">Chen JJ, Chan P, Paes B, et al. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS One 2015; 10:e0134711.</a></li></ol></div><div id="topicVersionRevision">Topic 15389 Version 65.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070304" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349312" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24367040" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/173995" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Respiratory syncytial virus infections within families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/173995" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Respiratory syncytial virus infections within families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/173995" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Respiratory syncytial virus infections within families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578197" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Routine isolation procedure vs routine procedure supplemented by use of masks and goggles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3773177" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3600729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15236847" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : RSV outbreak in a paediatric intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2677595" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2348292" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15048056" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15048056" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37616235" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37616235" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726528" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35235726" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37018470" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38157500" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38157500" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38157500" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070315" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31358666" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : AAP Publications Reaffirmed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29204660" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29204660" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187309" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398871" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk Factors for Hospitalization for Respiratory Syncytial Virus Infection: A Population-based Cohort Study of Danish Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571236" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694935" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30093540" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266507" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30279156" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Question 1: Palivizumab for all children with Down syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32332221" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Respiratory Syncytial Virus-related Death in Children With Down Syndrome: The RSV GOLD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24929631" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596098" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Children with Down syndrome are high-risk for severe respiratory syncytial virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27537430" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Down's syndrome is a risk factor for severe lower respiratory tract infection due to respiratory syncytial virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25442868" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk factors associated with death in patients with severe respiratory syncytial virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165619" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Respiratory syncytial virus infection in Navajo and White Mountain Apache children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643844" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065863" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26511956" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28443266" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308481" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720836" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782771" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18368063" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071285" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Compliance with prophylaxis for respiratory syncytial virus infection in a home setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174866" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776822" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26924927" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177891" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177891" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26237402" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
